This is important for patients with MASH who may be receiving treatments for other comorbidities, such as glucagon-like peptide-1 (GLP-1) analogs for diabetes and weight management, that are associated with gastrointestinal AEs35,36. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.